What is a veterinary clinical TRIAL?


​A veterinary clinical trial is a scientific investigation conducted to evaluate the safety and efficacy of a drug, treatment, or procedure in animals. 

We have a strong work ethic where integrity and commitment to animal welfare are paramount.
​We ensure that our developments are scientifically sound and contribute to animal well-being.
​Therefore, everything we do is tested multiple times and backed by data. 

​More info: [email protected] o +598 096 498 300



 The objective of the study  is to validate the development of Xep01, for the treatment of chronic pain associated with osteoarthritis in dogs.


​

​

​The treatment consist of the Xep01 vaccine that stimulates the production of antibodies that decrease pain and inflammation in vaccinated dogs. 



​All costs associated with the study, such as diagnosis, laboratory analysis during the trial, and clinical follow-up, will be covered by the sponsoring company.

​

WHO CAN PARTICIPATE IN OUR CLINICAL TRIAL?

Inclusion criteria
  • To be healthy, beyond osteoarthritis, at the time of recruitment, that is, not to present other concomitant diseases (cardiac, renal, neurological, etc.

  • To present a history of chronic pain (3 months of evolution) to the manipulation of at least 1 limb (signs of osteoarthritis will be confirmed by conducting a radiological study).

  • To have a weight greater than 8 kilograms and be older than 1 year, without distinction of race or sex. 
​
  • ​To present a value of moderate pain intensity on the pain scales that will be applied, which must be consistent with a moderate osteoarthritis process. 
exclusion criteria
  • Patients who have concomitant diseases (infectious-contagious, neurological, renal, oncological, etc)

  • Patients whose guardians plan to make changes of residence, introduction of new pets or people to the home, or plan to travel during the course of the trial. 
 
  • Canines that do not positively tolerate manipulation and interaction with the Veterinarian. 
 
  • Pregnant, lactating or breeding females that will be used during the course of the trial. 
 
  • Patients who have participated in any clinical trial in the last 30 days, were previously treated with monoclonal antibodies, and/or who may potentially present any adverse reaction to the active principle. 
​
  • Canines that are undergoing tratment with any type of corticosteroids that cannot be interrupted and those that during the clinical trial period are immunized (annual vaccine).

what do we know about the efficacy ​
​and security of ​our technology?



​Previous animal studies have demonstrated that the Xep01 vaccine is safe, well-tolerated, and effective for treating pain associated with canine osteoarthritis. 

The vaccine has been shown to provide long-lasting pain relief, improve mobility and anial well-being, and reduce the need for pain medication in dogs with advanced osteoarthritis.

Most recently, a safety pilot trial in healthy dogs confirmed that vaccination with Xep01 does not cause any significant local or systemic adverse effects.

Overall, the evidence from these studies supports the safety and efficacy of the Xep01 vaccine for managing pain and improving outcomes in canine osteoarthritis patients.